Merck KGaA Sells Global Clinical Chemistry Business To DiaSys
In a strategic move to focus on core businesses in chemicals, Merck KGaA announced today that it will sell its global Clinical Chemistry business to DiaSys Diagnostic Systems GmbH & Co. KG, effective February 28, 2003. Both parties agreed not to disclose financial details of the transaction. Merck's global Clinical Microbiology and Microscopy/Cell Diagnostics business is not affected by this step.
Global customer relationships of Merck, including supply and service, will be transferred to DiaSys. Merck will continue manufacturing specific products during a transition period of one year. Merck employees involved in the transaction will be given new responsibilities within the company.
Merck's Clinical Chemistry business achieved sales of EUR 7,5 million in 2001. It is mainly represented by standardized diagnostic test kits used in hospitals and private medical laboratories. Main products comprise test kits for diabetes, heart, kidney, inflammation, liver, lipid metabolism, pancreas and other diseases as well as controls and calibrators. About one-third of the business is located in Germany, 30 percent in other European countries. Asia and Latin America each account for around 20 percent.
Weitere News aus dem Ressort Wirtschaft & Finanzen
Holen Sie sich die Chemie-Branche in Ihren Posteingang
Ab sofort nichts mehr verpassen: Unser Newsletter für die chemische Industrie, Analytik, Labor und Prozess bringt Sie jeden Dienstag und Donnerstag auf den neuesten Stand. Aktuelle Branchen-News, Produkt-Highlights und Innovationen - kompakt und verständlich in Ihrem Posteingang. Von uns recherchiert, damit Sie es nicht tun müssen.
